Skip to main content
. 2023 Jan 20;47(4):251–256. doi: 10.1038/s41366-023-01254-z

Fig. 1. Major adverse cardiovascular events.

Fig. 1

Freedom of major adverse cardiovascular events (MACE) or all-cause mortality up to 8 years after initiation of GLP-1 receptor agonists or metabolic or bariatric surgery in persons with type 2 diabetes.